Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

PD-1 inhibitor monotherapy

10 evidence topics · 7 sources

KEYNOTE-048 design, stratification, and population

“The efficacy of KEYTRUDA was investigated in KEYNOTE-048 (NCT02358031), a randomized, multicenter, open-label, active-controlled trial conducted in 882 patients with metastatic HNSCC who had not previously received systemic therapy for metastatic disease or with recurrent disease who were considered incurable by local therapies.” (opens the source at this quote in a new tab)

“Randomization was stratified by tumor PD-L1 expression (TPS ≥50% or <50%) according to the PD-L1 IHC 22C3 pharmDx assay, HPV status according to p16 IHC (positive or negative), and ECOG PS (0 vs. 1).” (opens the source at this quote in a new tab)

“A retrospective re-classification of patients’ tumor PD-L1 status according to CPS using the PD-L1 IHC 22C3 pharmDx assay was conducted using the tumor specimens used for randomization.” (opens the source at this quote in a new tab)

“The main efficacy outcome measures were OS and PFS as assessed by BICR according to RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ) sequentially tested in the subgroup of patients with CPS ≥20, the subgroup of patients with CPS ≥1, and the overall population.” (opens the source at this quote in a new tab)

“Twenty-two percent of patients’ tumors were HPV-positive, 23% had PD-L1 TPS ≥50%, and 95% had Stage IV disease (Stage IVA 19%, Stage IVB 6%, and Stage IVC 70%).” (opens the source at this quote in a new tab)

“Eighty-five percent of patients’ tumors had PD-L1 expression of CPS ≥1 and 43% had CPS ≥20.” (opens the source at this quote in a new tab)

KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups
EndpointCPS ≥1CPS ≥20
Participants, pembrolizumab 200 mg every 3 weeks“n=257”“n=133”
Participants, cetuximab with platinum and FU“n=255”“n=122”
Median OS, pembrolizumab, months (95% CI)“12.3 (10.8, 14.9)”“14.9 (11.6, 21.5)”
Median OS, cetuximab with platinum and FU, months (95% CI)“10.3 (9.0, 11.5)”“10.7 (8.8, 12.8)”
OS hazard ratio (95% CI)“0.78 (0.64, 0.96)”“0.61 (0.45, 0.83)”
Median PFS, pembrolizumab, months (95% CI)“3.2 (2.2, 3.4)”“3.4 (3.2, 3.8)”
Median PFS, cetuximab with platinum and FU, months (95% CI)“5.0 (4.8, 5.8)”“5.0 (4.8, 6.2)”
PFS hazard ratio (95% CI)“1.15 (0.95, 1.38)”“0.97 (0.74, 1.27)”
ORR, pembrolizumab (95% CI)“19% (14.5, 24.4)”“23% (16.4, 31.4)”
ORR, cetuximab with platinum and FU (95% CI)“35% (29.1, 41.1)”“36% (27.6, 45.3)”
Median duration of response, pembrolizumab, months (range)“20.9 (1.5+, 34.8+)”“20.9 (2.7, 34.8+)”
Median duration of response, cetuximab with platinum and FU, months (range)“4.5 (1.2+, 28.6+)”“4.2 (1.2+, 22.3+)”
KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival

“Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy

“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote